In this issue:
Outcomes following a second alloHSCT
Outcomes following a third alloHSCT
Late effects after alloHSCT in patients aged ≤21 years with NMDs
Outcomes of MUD & mMUD alloHSCT with PTCy-based GvHD prophylaxis
Vedolizumab + standard GvHD prophylaxis after unrelated donor alloHSCT
cGvHD-associated disabilities after alloHSCT
REACH5: ruxolitinib in paediatric cGvHD following alloHSCT
Posoleucel to reduce risk of CSIs following alloHSCT
Please login below to download this issue (PDF)